Brokerages forecast that Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) will post ($0.55) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Syros Pharmaceuticals’ earnings, with estimates ranging from ($1.03) to ($0.34). Syros Pharmaceuticals reported earnings of ($0.39) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 41%. The business is scheduled to issue its next quarterly earnings results on Thursday, May 6th.
On average, analysts expect that Syros Pharmaceuticals will report full year earnings of ($1.93) per share for the current financial year, with EPS estimates ranging from ($3.52) to ($1.27). For the next year, analysts expect that the company will report earnings of ($1.69) per share, with EPS estimates ranging from ($1.87) to ($1.50). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that follow Syros Pharmaceuticals.
Syros Pharmaceuticals (NASDAQ:SYRS) last released its earnings results on Thursday, March 4th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.08). Syros Pharmaceuticals had a negative return on equity of 111.54% and a negative net margin of 743.58%.
A number of research firms have recently commented on SYRS. Zacks Investment Research cut Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, February 24th. Alliance Global Partners dropped their price objective on Syros Pharmaceuticals from $18.00 to $14.00 in a research report on Friday, March 5th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $16.50.
In related news, Director Richard A. Young sold 3,750 shares of the stock in a transaction on Tuesday, February 16th. The stock was sold at an average price of $12.05, for a total transaction of $45,187.50. Following the sale, the director now directly owns 321,711 shares of the company’s stock, valued at $3,876,617.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 14.80% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the business. Principal Financial Group Inc. bought a new position in Syros Pharmaceuticals in the fourth quarter valued at about $114,000. JPMorgan Chase & Co. lifted its holdings in Syros Pharmaceuticals by 0.4% in the fourth quarter. JPMorgan Chase & Co. now owns 735,872 shares of the company’s stock valued at $7,984,000 after acquiring an additional 3,146 shares during the period. Jane Street Group LLC bought a new position in Syros Pharmaceuticals in the fourth quarter valued at about $597,000. Samsara BioCapital LLC lifted its holdings in Syros Pharmaceuticals by 55.5% in the fourth quarter. Samsara BioCapital LLC now owns 2,189,199 shares of the company’s stock valued at $21,837,000 after acquiring an additional 781,250 shares during the period. Finally, Orbimed Advisors LLC bought a new position in Syros Pharmaceuticals in the fourth quarter valued at about $16,953,000.
Shares of NASDAQ SYRS traded up $0.06 during trading on Friday, reaching $6.99. The company had a trading volume of 24,287 shares, compared to its average volume of 755,185. Syros Pharmaceuticals has a 12-month low of $6.40 and a 12-month high of $15.65. The stock has a market cap of $430.86 million, a PE ratio of -4.17 and a beta of 2.01. The business’s 50-day moving average is $8.80 and its 200 day moving average is $9.72. The company has a quick ratio of 3.51, a current ratio of 3.51 and a debt-to-equity ratio of 0.44.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and phase III clinical trial for patents with myelodysplastic syndrome; SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors; and SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia.
Recommended Story: Cost of Equity
Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.